Abstract and Introduction
Introduction
HIV preexposure prophylaxis (PrEP) provides more than 99% protection against HIV transmission when taken as indicated. Side effects of PrEP are low, but costs of the medication and related clinical care are high. Efforts to end the HIV epidemic hinge on PrEP, with both mathematical models and real-world data suggesting that bringing PrEP to scale among groups with high HIV incidence will substantially affect the HIV epidemic.[1] The US Centers for Disease Control and Prevention (CDC) provides guidance for PrEP indication to assist clinicians in determining who should be provided PrEP.
Am J Public Health. 2020;110(3):267-268. © 2020 American Public Health Association
